Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0XFTRM
ADC Name	Bevacizumab vedotin
Synonyms	Bevacizumab-Val-Cit-PABC-MMAE; Bevacizumab Val Cit PABC MMAE Click to Show/Hide
Drug Status	Investigative
Indication	In total 3 Indication(s) Breast cancer [ICD11:2C60-2C65] Investigative Glioblastoma [ICD11:2A00] Investigative Hepatocellular carcinoma [ICD11:2C12] Investigative
Drug-to-Antibody Ratio	1.9
	3D MOL	2D MOL
Antibody Name	Bevacizumab		Antibody Info
Antigen Name	Vascular endothelial growth factor A (VEGFA)		Antigen Info
Payload Name	Monomethyl auristatin E		Payload Info
Therapeutic Target	Microtubule (MT)		Target Info
Linker Name	Mc-Val-Cit-PABC		Linker Info
Conjugate Type	Random conjugation through reduced inter-chain cysteines.
Combination Type	Vedotin

General Information of The Activity Data Related to This ADC

Revealed Based on the Cell Line Data

Click To Hide/Show 3 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Half Maximal Inhibitory Concentration (IC50)	0.14	ug/mL	MCF-7 cells	Invasive breast carcinoma
Half Maximal Inhibitory Concentration (IC50)	0.65	ug/mL	Hep-G2 cells	Hepatoblastoma
Half Maximal Inhibitory Concentration (IC50)	14.17	ug/mL	U-87MG cells	Glioblastoma

Full List of Activity Data of This Antibody-drug Conjugate

Revealed Based on the Cell Line Data

Click To Hide/Show 3 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.14 ug/mL	Positive VEGFA expression (VEGFA +++/++)
Method Description	The anti-proliferative activity of Bevacizumab Vedotin and Bevacizumab against three different cell lines was determined by MTT method.
In Vitro Model	Invasive breast carcinoma	MCF-7 cells		CVCL_0031
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.65 ug/mL	Positive VEGFA expression (VEGFA +++/++)
Method Description	The anti-proliferative activity of Bevacizumab Vedotin and Bevacizumab against three different cell lines was determined by MTT method.
In Vitro Model	Hepatoblastoma	Hep-G2 cells		CVCL_0027
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	14.17 ug/mL	Positive VEGFA expression (VEGFA +++/++)
Method Description	The anti-proliferative activity of Bevacizumab Vedotin and Bevacizumab against three different cell lines was determined by MTT method.
In Vitro Model	Glioblastoma	U-87MG cells		CVCL_0022

References

Ref 1	Discovery of novel antibody-drug conjugates bearing tissue protease specific linker with both anti-angiogenic and strong cytotoxic effects. Bioorg Chem. 2023 Aug;137:106575. doi: 10.1016/j.bioorg.2023.106575. Epub 2023 Apr 26.